E-Cadherin Expression in Blastic Plasmacytoid Dendritic Cell Neoplasms: An Unrecognized Finding and Potential Diagnostic Pitfall

Int J Surg Pathol. 2021 May;29(3):289-293. doi: 10.1177/1066896920938130. Epub 2020 Jul 1.

Abstract

E-cadherin is expressed in hematopoietic erythroid precursors, but to our knowledge, its expression in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has not been described. We report a case of BPDCN showing strong expression of E-cadherin, arising in a patient with history of primary myelofibrosis. Four more cases of BPDCN tested all showed strong expression of E-cadherin. Lack of awareness of this pattern of expression may lead to erroneous diagnosis of acute erythroid leukemia. It is increasingly becoming important to correctly identify this group of neoplasms, as approved new anti-CD123-targeted therapies are becoming available.

Keywords: E-cadherin expression; acute erythroid leukemia; anti-CD123–targeted therapies; blastic plasmacytoid dendritic cell neoplasms; erroneous diagnosis; primary myelofibrosis.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD / analysis*
  • Bone Marrow / pathology*
  • Cadherins / analysis*
  • Cell Transformation, Neoplastic
  • Dendritic Cells / pathology*
  • Diagnosis, Differential
  • Fatal Outcome
  • Female
  • Hematologic Neoplasms / diagnosis*
  • Hematologic Neoplasms / pathology
  • Humans
  • Leukemia, Erythroblastic, Acute / diagnosis
  • Leukemia, Erythroblastic, Acute / pathology
  • Middle Aged
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / pathology*

Substances

  • Antigens, CD
  • CDH1 protein, human
  • Cadherins

Supplementary concepts

  • Acute erythroleukemia